share_log

Barclays Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55

Benzinga ·  Nov 8 13:06  · Ratings

Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target from $76 to $55.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment